May 23, 2022 / 08:00AM GMT
Göran Forsberg - Cantargia AB - CEO
Thank you so much. It's a pleasure to present our Q1 report. And if we move to slide 2 and then to slide 3, I can say that it's me, Forsberg and the CFO of Cantargia, Bengt Jöndell, who would do his presentation.
And then the going to slide number 4. We've been running through in a way and at a period with lots of news flow, but lots of news flow had the one chance of the lead project, that's been around stocking up new trials, so first patient in and things like that. So that's a very important event because it means that new activities are starting.
But from the results point of view, we have had much more, let's say, progress in the second project, the CAN10 program where we present new results in systemic sclerosis during the period. And also yesterday, we could present some very exciting results in atherosclerosis, which is not the lead indication, but still very exciting and really a new opportunity for our program.
And another important event also, which happened already early January, it's that we signed an
Q1 2022 Cantargia AB Earnings Call Transcript
May 23, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers